IQWiG invites to its Autumn Symposium 2015

IQWiG

7 September 2015 - Benefit assessments of medical interventions are conducted to answer the question: What is the benefit and possible harm of the intervention for patients? It has been repeatedly demanded to use not only the results from “artificial” randomized controlled trials to answer this question, but also data from the actual health care setting (real world). This raises some obvious questions: What are the characteristics of these data and what specific contribution could they make to benefit assessments? What requirements would they have to meet to provide a basis for valid conclusions? Is it acceptable to accelerate drug approval on the basis of a weaker evidence base, referring to later real-world data?

This year’s Autumn Symposium will focus on these questions: International and national experts from research and the health care systems will present their answers to these questions for discussion.

For more details, go to: https://www.iqwig.de/en/press/press-releases/press-releases/iqwig-invites-to-its-autumn-symposium-2015.6887.html

Michael Wonder

Posted by:

Michael Wonder